Introduction

The spleen is a significant organ of the hematologic and reticuloendothelial systems. It is an intraperitoneal organ located in the left upper quadrant of the abdomen posterior and lateral to the stomach.[1] The spleen is situated anatomically behind the 9 and 11 ribs on the left side of the body.

Cellular Level

The spleen contains two major units: white pulp and red pulp.[2] The white pulp is composed of lymphatic tissue surrounding a central arteriole and contains mainly white blood cells that are involved in the initiation of the adaptive immune response. The innermost area of the white pulp, the germinal center, contains B-cells while the surrounding marginal zone contains T-cells.[3] The marginal zone is surrounded by a periarteriolar lymphoid sheath (PALS), which also contains T-cells. White pulp throughout the spleen is surrounded by red pulp. The red pulp is composed of splenic cords (Cords of Billroth) and a large volume of venous sinuses, which gives the structure its characteristic red appearance under a microscopic. The splenic cords provide the organ structure through reticulin and fibrils. The cords also contain a reservoir of monocytes to aid in wound healing. Splenic cords lead to splenic sinuses where macrophages respond to antigens and filter abnormal or aging erythrocytes out of blood flow.[4]

A thin, fibrous capsule covers the spleen from which trabeculae arise. Trabeculae are fibrous bands transporting blood vessels to and from the splenic pulp.[5]

Development

The spleen derives from a mass of mesenchymal cells in the dorsal mesogastrium, later known as the greater omentum.[6] Vasculature of the primordial spleen begins to develop in the fifth week when hematogenesis (blood cell formation) first develops along the aorta and parts of the mesenchyme. When the fetal period begins in week 9, erythropoiesis functions mainly in the liver and partially in the spleen. By the end of week 12, the spleen is taking a larger role in erythropoiesis as the major site of activity until week 28 when the bone marrow becomes the primary site. In a normal adult, the spleen is located intraperitoneally in the left upper abdominal quadrant near the tail of the pancreas and above the splenic flexure.[7] The spleen is supplied by blood from the splenic artery (branching off of the celiac trunk) and drained by the splenic vein (uniting with the superior mesenteric vein to form the hepatic portal vein).[6]

Function

In utero, the spleen is partially responsible for hemoglobin synthesis from the 10th through the 25th week of pregnancy. After birth, the primary function of the spleen shifts to the following major roles: 

• Filtration 
• Iron metabolism
• Prevention of infection
• Red blood cell and platelet storage

Filtration of erythrocytes and platelets occurs via splenic cords in the red pulp. Young, flexible red blood cells pass through the epithelial cells of the splenic cords and continue through blood flow. On the other hand, older, larger, and deformed red blood cells are trapped by the splenic cords and phagocytosed by macrophages waiting on the reticulum and sinus endothelium.[8]

Furthermore, splenic macrophages in red pulp are specialized to recycle iron from the breakdown of senescent and damaged red blood cells.[9] Macrophages can either store ingested iron in the cytoplasm or export it via ferritin into the bloodstream.[10] 

Not only does the spleen play a role in the breakdown of red blood cells, but it can also play a role in hematopoiesis. While not a typical function, in pathologic conditions, such as beta-thalassemia major, extramedullary hematopoiesis may occur to help the bone marrow compensate for the hemolysis taking place.

Infection prevention occurs by two major mechanisms: phagocytic filtration of the bloodstream and production of opsonizing antibodies. As mentioned above, macrophages supervise the flow of red blood cells, platelets, as well as microorganisms through the splenic cords.[11] Additionally, in the follicle of the white pulp, infectious antigens and blood-borne pathogens are presented by antigen-presenting cells.[12] This process initiates the activation of T-cells and B-cells, which eventually leads to the production of opsonizing antibodies.[13] After opsonization, macrophages, dendritic cells, and neutrophils phagocytose the antigen.[14] Opsonization is essential to clear particular microorganisms like encapsulated bacteria and intra-erythrocytic parasites.[15] The spleen is the largest secondary lymphoid organ in an adult human.[16]

As a reservoir for blood, the spleen weights about 100 g. The organ can respond to sympathetic stimulation by contracting its fibroelastic capsule and trabeculae to increase systemic blood supply. In particular, this vital function takes place during hemorrhage. About 25% to 30% of red blood cells (RBCs) are stored in the spleen, along with about 25% of platelets normally sequestered in the spleen.

Related Testing

While not highly sensitive or specific, the clinician can perform a physical exam to test for splenomegaly. Laboratory work that can help assess splenic activity is a complete blood count (CBC) complimented by a peripheral blood smear. Abnormalities in quantity or quality of cell types can provide evidence of pathology involving the spleen. In addition to the physical exam and laboratory testing, there is a variety of imaging modalities to visualize the spleen.[17]

A focused assessment with sonography in trauma (FAST) exam uses ultrasound to assess for the presence of fluid where it should not be in trauma evaluation. A FAST exam looks at four windows: pericardial window, Morrison’s pouch (right upper quadrant between liver and right kidney), left upper quadrant (between the spleen and left kidney), and the suprapubic region to look at the bladder and pelvis. The exam is considered positive with fluid in any of these spaces, and combination with hemodynamic instability is an indication for exploratory laparotomy. With positive fluid in the pericardial window, a pericardiocentesis is an appropriate followup.[18]

Computed tomography (CT) and magnetic resonance imaging (MRI) are beneficial tools to visualize and characterize the spleen. Both modalities function to measure the spleen and identify physical abnormalities. While not necessary, the use of contrast can aid in tracing blood flow and help identify any leaks or pathologic fluid collection.[19]

A biopsy of the spleen is rarely necessary secondary to concerns of a risk of bleeding. More often, a blood marrow biopsy is preferable for the evaluation of blood cells for cancer.[19]

Pathophysiology

Extravascular Hemolysis 

Hemolysis of red blood cells can classify as intravascular or extravascular. As the name implies, intravascular hemolysis is the breakdown of red blood cells in vessels. Extravascular hemolysis is the breakdown of red blood cells in the reticuloendothelial system, such as the spleen and liver. In extravascular hemolysis, it is the macrophages that perform the hemolysis. Patients with extravascular hemolysis present with splenomegaly secondary to splenic hypertrophy and jaundice due to the increased levels of unconjugated bilirubin from broken down blood cells. Laboratory results can reveal anemia, unconjugated hyperbilirubinemia, and an increased reticulocyte count, which reflects a good bone marrow response to the anemia. Because of the increased bilirubin, patients with extravascular hemolysis are at an increased risk of bilirubin gallstones, which can lead to biliary pathology. Conditions that can cause extravascular hemolysis include sickle cell disease, hereditary spherocytosis, hemoglobin C, malaria, IgG immune hemolytic anemia, and beta-thalassemia major. Treatment typically focuses on the underlying cause, with splenectomy providing a cure in some cases.[20][21][22]

Splenomegaly 

Splenomegaly is the abnormal enlargement of the spleen with a length greater than 10 cm. This irregularity can result from multiple types of mechanisms: hypertrophy, infiltration, congestion, myeloproliferative, and neoplastic. RBC work hypertrophy suggests increased normal splenic function by filtering large amounts of abnormal erythrocytes from the circulation. Examples of this type include hereditary spherocytosis and sickle cell anemia.

Meanwhile, immune response work hypertrophy from chronic systemic infections or immune-mediated disorders can also cause splenomegaly. Malignant, benign, or metabolic conditions infiltrate the spleen in cases like sarcoidosis and some neoplasms leading to splenomegaly.  Congestive splenomegaly is secondary to obstruction of blood flow and, therefore, engorged with blood in the red pulp. Myeloproliferative disorders include chronic myeloid metaplasia. Neoplastic origins include chronic lymphocytic leukemia and lymphoma.[23]

Palpation by percussion evaluates for an enlarged spleen. This physical exam is not diagnostic of the disease. Diagnosis is more precise when measured by imaging studies like CT, MRI, or US. Splenomegaly may be idiopathic or secondary to an underlying disease.[24]

Hyposplenia/Post-Splenectomy/Asplenia Immunization and Antibiotic prophylaxis 

There are a variety of causes for splenic dysfunction ranging from extravascular hemolysis to sickle cell disease and trauma. Due to the spleen playing a large role in the immune system, recognizing splenic dysfunction or preparing to lose the spleen is critical in preventing death secondary to asplenic sepsis. For any patient with splenic dysfunction, they must receive prophylactic vaccination against encapsulated organisms, such as Streptococcus pneumoniae, Neisseria meningitides, and Haemophilus influenzae. Due to the increased risk of a Streptococcus pneumoniae infection following infection from the influenza virus, a- or hypo-splenic patients should receive yearly influenza vaccinations as well. Because vaccinations do not cover all serotypes of the organism, many patients receive either daily prophylactic antibiotics, usually penicillin, or an emergency supply should they develop a fever. The timing of implementation for these practices depends on the reason for splenic dysfunction. In patients with functional asplenia or hyposplenism, such as in sickle cell disease, prophylaxis should begin as soon as possible. In cases of elective spleen surgery, prophylaxis should begin two weeks before surgery. In emergency surgery, it should commence two weeks after surgery.[25]

Portal Hypertension 

Portal hypertension is a result of increased pressure in the portal venous system, which drains the stomach, intestine, spleen, and pancreas. As portal hypertension worsens, the venous congestion of the splenic vein can cause splenomegaly. The spleen undergoes hyperplasia and fibrosis, which further increases the blood supply to the spleen, exacerbating the condition. With this hyperplasia, there has been evidence that the white pulp increases in size, possibly indicating an alteration in immune system function. Sometimes, a splenorenal shunt can help reduce the burden of portal hypertension by reducing the contribution of blood by the splenic vein.[26][27]

Clinical Significance

Immune Thrombocytopenic Purpura (ITP) 

ITP appears to be an autoimmune condition resulting in thrombocytopenia, petechiae/purpura, and bleeding from mucosal surfaces. There have been many antibodies implicated in the pathogenesis of ITP with the two main autoantibodies being against IgG and the glycoprotein (GP) IIb/IIIa complex on platelets. Platelets tagged by these autoantibodies then get broken down by phagocytes in the spleen, resulting in thrombocytopenia. Without platelets to form the platelet plug, which is the first step of hemostasis, the patient becomes more susceptible to bleeding. Most patients with ITP only have minor bleeds, such as nosebleeds or conjunctival bleeds. However, these patients are at risk of severe bleeds, and that risk helps guide management. ITP tends to affect children around five years old or older adults. In children, ITP typically presents with a sudden onset, usually following a microbial illness and is brief. In adults, it typically presents with insidious onset and is a chronic condition. In both patient populations, there must be a high index of suspicion, and ITP is usually a diagnosis of exclusion. A CBC and peripheral blood smear are typically performed in the initial evaluation. In adults, it is essential to rule out ITP secondary to other autoimmune diseases, so an anti-nuclear antibody (ANA) and autoantibodies specific for other conditions may be tested as well. A more specific test for ITP would be autoantibodies against IgG and GP IIb/IIIa. In children, treatment is generally conservative, as ITP is typically transient. Adults usually require treatment. Prednisone is the first-line treatment in adults and can also be used to treat children. IVIG can also be used to reduce or eliminate causative autoantibodies and is typically used before steroids in children and after steroids in adults. In cases refractory to medical management, a splenectomy is an option as most platelet breakdown occurs there.[28]

Trauma 

The spleen is one of the most commonly injured organs in blunt abdominal trauma. While it sometimes suffers injury in penetrating trauma, this is less common. Like with other traumatic injuries, the primary focus taking care of a trauma patient is resuscitation and rapid detection of serious injuries following the advanced trauma life support (ATLS) protocol. After performing a thorough physical exam and fluid resuscitation, a FAST exam is typically performed early in the evaluation of a trauma patient, sometimes as a part of the physical exam. Because the FAST exam can sometimes miss intraparenchymal injuries, a high degree of suspicion is necessary. The rest of the workup largely depends on hemodynamic stability. If the patient is hemodynamically stable, regardless of FAST exam results, the patient should undergo imaging using a CT scan. Active extravasation and blush of contrast are indicative of active bleeding. If the patient is hemodynamically unstable with a positive FAST exam, the patient can undergo exploratory laparotomy without further workup.

Splenic injury in trauma generally fall into five grades, according to the American Association for the Surgery of Trauma (AAST), which typically categorizes the injuries as lacerations, hematoma, or vascular and describe the extent of injury to vessels or specific splenic tissue. Injury grades I-III are most commonly treated in the hospital using medical management. Surgical management is an option if the patient’s condition does not improve or respond to medical management. Injuries greater than grade III are considered high-grade and typically treated using surgery, although select cases can receive medical management. Procedural treatment of splenic injury can range from the relatively non-invasive angioembolization to partial or total splenectomy. Medical management generally consists of symptomatic treatment with serial CBCs to trend the hemoglobin. Serial imaging is also an option if there is suspicion for bleeding, such as decreasing hemoglobin, or signs of peritonitis. A bleed may present later as a hematoma, the spleen itself, or another collection of fluid may have ruptured between initial survey and admission.[29][30]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Baas J, Senninger N, Elser H. [The reticuloendothelial system. An overview of function, pathology and recent methods of measurement]. Z Gastroenterol. 1994 Feb;32(2):117-23. [PubMed: 8165827]

2.

Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005 Aug;5(8):606-16. [PubMed: 16056254]

3.

Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009 Jul 31;325(5940):612-6. [PMC free article: PMC2803111] [PubMed: 19644120]

4.

Kraal G. Cells in the marginal zone of the spleen. Int Rev Cytol. 1992;132:31-74. [PubMed: 1555921]

5.

Freitas CR, Barbosa AA, Fernandes AL, Andrade ZA. Pathology of the spleen in hepatosplenic schistosomiasis. Morphometric evaluation and extracellular matrix changes. Mem Inst Oswaldo Cruz. 1999 Nov-Dec;94(6):815-22. [PubMed: 10585661]

6.

Patterson KD, Drysdale TA, Krieg PA. Embryonic origins of spleen asymmetry. Development. 2000 Jan;127(1):167-75. [PubMed: 10654610]

7.

Varga I, Galfiova P, Adamkov M, Danisovic L, Polak S, Kubikova E, Galbavy S. Congenital anomalies of the spleen from an embryological point of view. Med Sci Monit. 2009 Dec;15(12):RA269-76. [PubMed: 19946246]

8.

Barnhart MI, Lusher JM. Structural physiology of the human spleen. Am J Pediatr Hematol Oncol. 1979 Winter;1(4):311-30. [PubMed: 397778]

9.

Ganz T. Macrophages and Iron Metabolism. Microbiol Spectr. 2016 Oct;4(5) [PubMed: 27763254]

10.

Theurl I, Hilgendorf I, Nairz M, Tymoszuk P, Haschka D, Asshoff M, He S, Gerhardt LM, Holderried TA, Seifert M, Sopper S, Fenn AM, Anzai A, Rattik S, McAlpine C, Theurl M, Wieghofer P, Iwamoto Y, Weber GF, Harder NK, Chousterman BG, Arvedson TL, McKee M, Wang F, Lutz OM, Rezoagli E, Babitt JL, Berra L, Prinz M, Nahrendorf M, Weiss G, Weissleder R, Lin HY, Swirski FK. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver. Nat Med. 2016 Aug;22(8):945-51. [PMC free article: PMC4957133] [PubMed: 27428900]

11.

Bohnsack JF, Brown EJ. The role of the spleen in resistance to infection. Annu Rev Med. 1986;37:49-59. [PubMed: 3518612]

12.

Hey YY, Quah B, O'Neill HC. Antigen presenting capacity of murine splenic myeloid cells. BMC Immunol. 2017 Jan 11;18(1):4. [PMC free article: PMC5225582] [PubMed: 28077081]

13.

Sunshine GH, Mitchell TJ. Antigen presentation by spleen dendritic cells. J Invest Dermatol. 1985 Jul;85(1 Suppl):110s-114s. [PubMed: 2409180]

14.

Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013 Nov 14;39(5):806-18. [PMC free article: PMC3912742] [PubMed: 24238338]

15.

Deng HK, Le Rhun D, Lecuelle B, Le Naour E, Vayssier-Taussat M. Role of the spleen in Bartonella spp. infection. FEMS Immunol Med Microbiol. 2012 Feb;64(1):143-5. [PubMed: 22098417]

16.

Mebius RE, Nolte MA, Kraal G. Development and function of the splenic marginal zone. Crit Rev Immunol. 2004;24(6):449-64. [PubMed: 15777163]

17.

McIntyre OR, Ebaugh FG. Palpable spleens in college freshmen. Ann Intern Med. 1967 Feb;66(2):301-6. [PubMed: 6016543]

18.

Waheed KB, Baig AA, Raza A, Ul Hassan MZ, Khattab MA, Raza U. Diagnostic accuracy of Focused Assessment with Sonography for Trauma for blunt abdominal trauma in the Eastern Region of Saudi Arabia. Saudi Med J. 2018 Jun;39(6):598-602. [PMC free article: PMC6058749] [PubMed: 29915855]

19.

Vancauwenberghe T, Snoeckx A, Vanbeckevoort D, Dymarkowski S, Vanhoenacker FM. Imaging of the spleen: what the clinician needs to know. Singapore Med J. 2015 Mar;56(3):133-44. [PMC free article: PMC4371192] [PubMed: 25820845]

20.

Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015 Jun;29(3):455-71. [PubMed: 26043385]

21.

Kurtoǧllu AU, Koçtekin B, Kurtoǧlu E, Yildiz M, Bozkurt S. Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients. Cent Eur J Immunol. 2017;42(1):78-84. [PMC free article: PMC5470617] [PubMed: 28680334]

22.

Sakamoto TM, Canalli AA, Traina F, Franco-Penteado CF, Gambero S, Saad ST, Conran N, Costa FF. Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clin Biochem. 2013 Dec;46(18):1798-803. [PubMed: 24060729]

23.

McKenzie CV, Colonne CK, Yeo JH, Fraser ST. Splenomegaly: Pathophysiological bases and therapeutic options. Int J Biochem Cell Biol. 2018 Jan;94:40-43. [PubMed: 29191734]

24.

Curovic Rotbain E, Lund Hansen D, Schaffalitzky de Muckadell O, Wibrand F, Meldgaard Lund A, Frederiksen H. Splenomegaly - Diagnostic validity, work-up, and underlying causes. PLoS One. 2017;12(11):e0186674. [PMC free article: PMC5685614] [PubMed: 29135986]

25.

Bonanni P, Grazzini M, Niccolai G, Paolini D, Varone O, Bartoloni A, Bartalesi F, Santini MG, Baretti S, Bonito C, Zini P, Mechi MT, Niccolini F, Magistri L, Pulci MB, Boccalini S, Bechini A. Recommended vaccinations for asplenic and hyposplenic adult patients. Hum Vaccin Immunother. 2017 Feb;13(2):359-368. [PMC free article: PMC5328222] [PubMed: 27929751]

26.

Bloom S, Kemp W, Lubel J. Portal hypertension: pathophysiology, diagnosis and management. Intern Med J. 2015 Jan;45(1):16-26. [PubMed: 25230084]

27.

Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 2002 Feb;34(2):144-50. [PubMed: 11926560]

28.

Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002 Mar 28;346(13):995-1008. [PubMed: 11919310]

29.

Coccolini F, Montori G, Catena F, Kluger Y, Biffl W, Moore EE, Reva V, Bing C, Bala M, Fugazzola P, Bahouth H, Marzi I, Velmahos G, Ivatury R, Soreide K, Horer T, Ten Broek R, Pereira BM, Fraga GP, Inaba K, Kashuk J, Parry N, Masiakos PT, Mylonas KS, Kirkpatrick A, Abu-Zidan F, Gomes CA, Benatti SV, Naidoo N, Salvetti F, Maccatrozzo S, Agnoletti V, Gamberini E, Solaini L, Costanzo A, Celotti A, Tomasoni M, Khokha V, Arvieux C, Napolitano L, Handolin L, Pisano M, Magnone S, Spain DA, de Moya M, Davis KA, De Angelis N, Leppaniemi A, Ferrada P, Latifi R, Navarro DC, Otomo Y, Coimbra R, Maier RV, Moore F, Rizoli S, Sakakushev B, Galante JM, Chiara O, Cimbanassi S, Mefire AC, Weber D, Ceresoli M, Peitzman AB, Wehlie L, Sartelli M, Di Saverio S, Ansaloni L. Splenic trauma: WSES classification and guidelines for adult and pediatric patients. World J Emerg Surg. 2017;12:40. [PMC free article: PMC5562999] [PubMed: 28828034]

30.

El-Matbouly M, Jabbour G, El-Menyar A, Peralta R, Abdelrahman H, Zarour A, Al-Hassani A, Al-Thani H. Blunt splenic trauma: Assessment, management and outcomes. Surgeon. 2016 Feb;14(1):52-8. [PubMed: 26330367]

Disclosure: Vaishali Kapila declares no relevant financial relationships with ineligible companies.

Disclosure: Chase Wehrle declares no relevant financial relationships with ineligible companies.

Disclosure: Faiz Tuma declares no relevant financial relationships with ineligible companies.